Immediate Impact
5 from Science/Nature 68 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Targeting ROS in cancer: rationale and strategies
2024 Standout
Works of Jude Ngang being referenced
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jude Ngang | 108 | 89 | 106 | 5 | 193 | |
| Christina M. Fennell | 109 | 99 | 147 | 7 | 279 | |
| Mathilde Borg Houlberg Thomsen | 77 | 60 | 142 | 7 | 263 | |
| Matteo Menotti | 57 | 46 | 79 | 5 | 122 | |
| Antonia Del Giudice | 85 | 54 | 104 | 5 | 206 | |
| Amanda Zucker | 115 | 66 | 90 | 6 | 233 | |
| Kathleen Klein Oros | 63 | 58 | 109 | 8 | 191 | |
| Bethany Kaplan | 62 | 33 | 92 | 4 | 151 | |
| Lauren Carcas | 67 | 53 | 91 | 5 | 180 | |
| Marta Román | 115 | 124 | 160 | 7 | 290 | |
| Sandra Liebs | 109 | 29 | 77 | 7 | 196 |
All Works
Loading papers...